CRISPR Therapeutics(CRSP) - 2023 Q2 - Quarterly Report

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 For the transition period from to . Switzerland Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Accelerated filer☐ ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standard ...